Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma

Cancer Letters

Volumn 404, Issue , 2017, Pages 62-69

  Calapre, Leslie ^a   Warburton, Lydia ^b   Millward, Michael ^b,c   Ziman, Mel ^a,d   Gray, Elin S ^a  

^a EDITH COWAN UNIVERSITY   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cell free DNA; Circulating tumour DNA; ctDNA; Liquid biopsy; Melanoma

Indexed keywords

B RAF KINASE INHIBITOR; CIRCULATING TUMOR DNA; DABRAFENIB; DNA; LACTATE DEHYDROGENASE; MELANOMA INHIBITORY ACTIVITY PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PROTEIN S100B; UNCLASSIFIED DRUG; TUMOR MARKER;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL HETEROGENEITY; CEREBROSPINAL FLUID ANALYSIS; CLONAL EVOLUTION; CUTANEOUS MELANOMA; DISEASE ASSOCIATION; DNA DETERMINATION; DNA METHYLATION; EPIGENETICS; GENE MUTATION; HUMAN; LIQUID BIOPSY; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTATIC MELANOMA; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; MUTATIONAL LOAD; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SHORT SURVEY; SKIN CARCINOGENESIS; TREATMENT RESPONSE; TUMOR VOLUME; BIOPSY; BLOOD; GENETICS; METABOLISM; NEOPLASM, RESIDUAL; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BIOPSY; DNA, NEOPLASM; HUMANS; MELANOMA; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING;

EID: 85025468650     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2017.06.030     Document Type: Review

References (93)

1. Luke, J.J., Flaherty, K.T., Ribas, A., Long, G.V., Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol., 2017.
2. Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364:26 (2011), 2507–2516.
3. Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:9839 (2012), 358–365.
4. V600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 15:4 (2014), 436–444.
5. Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R.C., Moriceau, G., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4:1 (2014), 80–93.
6. Van Allen, E.M., Wagle, N., Sucker, A., Treacy, D.J., Johannessen, C.M., Goetz, E.M., et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4:1 (2014), 94–109.
7. Rizos, H., Menzies, A.M., Pupo, G.M., Carlino, M.S., Fung, C., Hyman, J., et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20:7 (2014), 1965–1977.
8. Callahan, M.K., Flaherty, C.R., Postow, M.A., Checkpoint blockade for the treatment of advanced melanoma. Cancer Treat. Res. 167 (2016), 231–250.
9. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:26 (2015), 2521–2532.
10. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16:8 (2015), 908–918.
11. Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:10 (2014), 1020–1030.
12. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:8 (2010), 711–723.
13. O'Day, S.J., Maio, M., Chiarion-Sileni, V., Gajewski, T.F., Pehamberger, H., Bondarenko, I.N., et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21:8 (2010), 1712–1717.
14. Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11:2 (2010), 155–164.
15. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366:26 (2012), 2443–2454.
16. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:4 (2015), 320–330.
17. Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6:5 (2016), 479–491.
18. Bettegowda, C., Sausen, M., Leary, R.J., Kinde, I., Wang, Y., Agrawal, N., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med., 6(224), 2014 224ra24.
19. Wan, J.C.M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J.D., Caldas, C., et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer. 17:4 (2017), 223–238.
20. Canzoniero, J.V., Park, B.H., Use of cell free DNA in breast oncology. Biochim. Biophys. Acta (BBA) Rev. Cancer. 2016:2 (1865), 266–274.
21. Murtaza, M., Dawson, S.J., Pogrebniak, K., Rueda, O.M., Provenzano, E., Grant, J., et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun., 6, 2015, 8760.
22. Newman, A.M., Bratman, S.V., To, J., Wynne, J.F., Eclov, N.C., Modlin, L.A., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20:5 (2014), 548–554.
23. De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H., Ng, C., Nuciforo, P., et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25:9 (2014), 1729–1735.
24. Jamal-Hanjani, M., Wilson, G.A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T., et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann. Oncol. 27:5 (2016), 862–867.
25. De Mattos-Arruda, L., Mayor, R., Ng, C.K., Weigelt, B., Martinez-Ricarte, F., Torrejon, D., et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat. Commun., 6, 2015, 8839.
26. Dawson, S.-J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.-F., et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368:13 (2013), 1199–1209.
27. Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D.W., Kaper, F., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med., 4(136), 2012 136ra68–136ra68.
28. Tie, J., Kinde, I., Wang, Y., Wong, H.L., Roebert, J., Christie, M., et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26:8 (2015), 1715–1722.
29. Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R.J., et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med., 7(302), 2015 302ra133–302ra133.
30. Murtaza, M., Dawson, S.J., Tsui, D.W., Gale, D., Forshew, T., Piskorz, A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:7447 (2013), 108–112.
31. Wang, W., Song, Z., Zhang, Y., A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med. 6:1 (2017), 154–162.
32. Zheng, D., Ye, X., Zhang, M.Z., Sun, Y., Wang, J.Y., Ni, J., et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci. Rep., 6, 2016, 20913.
33. Sundaresan, T.K., Sequist, L.V., Heymach, J.V., Riely, G.J., Janne, P.A., Koch, W.H., et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin. Cancer Res. 22:5 (2016), 1103–1110.
34. Van Emburgh, B.O., Sartore-Bianchi, A., Di Nicolantonio, F., Siena, S., Bardelli, A., Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol. Oncol. 8:6 (2014), 1084–1094.
35. Premarket approval P150044 — Cobas EGFR MUTATION TEST V2. Cited 2016; Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150044.
36. Iressa: public assessment report — product information. Cited 2017; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdf.
37. Tagrisso: public assessment report — product information. Cited 2017; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004124/WC500202022.pdf.
38. Gray, E.S., Rizos, H., Reid, A.L., Boyd, S.C., Pereira, M.R., Lo, J., et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6:39 (2015), 42008–42018.
39. Ascierto, P.A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31:26 (2013), 3205–3211.
40. Sanmamed, M.F., Fernandez-Landazuri, S., Rodriguez, C., Zarate, R., Lozano, M.D., Zubiri, L., et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 61:1 (2015), 297–304.
41. Santiago-Walker, A., Gagnon, R., Mazumdar, J., Casey, M., Long, G.V., Schadendorf, D., et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin. Cancer Res. 22:3 (2016), 567–574.
42. Girotti, M.R., Gremel, G., Lee, R., Galvani, E., Rothwell, D., Viros, A., et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 6:3 (2016), 286–299.
43. Gonzalez-Cao, M., Mayo-de-Las-Casas, C., Molina-Vila, M.A., De Mattos-Arruda, L., Munoz-Couselo, E., Manzano, J.L., et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 25:6 (2015), 486–495.
44. Schreuer, M., Meersseman, G., Van Den Herrewegen, S., Jansen, Y., Chevolet, I., Bott, A., et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. J. Transl. Med., 14, 2016, 95.
45. Wong, S.Q., Raleigh, J.M., Callahan, J., Vergara, I.A., Ftouni, S., Hatzimihalis, A., et al. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precis. Oncol.(1), 2017, 1–14.
46. Knol, A.C., Vallee, A., Herbreteau, G., Nguyen, J.M., Varey, E., Gaultier, A., et al. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. Exp. Dermatol., 2016.
47. Lipson, E.J., Velculescu, V.E., Pritchard, T.S., Sausen, M., Pardoll, D.M., Topalian, S.L., et al. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J Immunother. Cancer, 2(1), 2014, 42.
48. Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann. Oncol., 2017.
49. Chang, G.A., Tadepalli, J.S., Shao, Y., Zhang, Y., Weiss, S., Robinson, E., et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol. Oncol. 10:1 (2016), 157–165.
50. Tsao, S.C., Weiss, J., Hudson, C., Christophi, C., Cebon, J., Behren, A., et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci. Rep., 5, 2015, 11198.
51. Long, G.V., Fung, C., Menzies, A.M., Pupo, G.M., Carlino, M.S., Hyman, J., et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat. Commun., 5, 2014, 5694.
52. Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco. Targets Ther. 8 (2015), 157–168.
53. Balgkouranidou, I., Chimonidou, M., Milaki, G., Tsarouxa, E.G., Kakolyris, S., Welch, D.R., et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Br. J. Cancer. 110:8 (2014), 2054–2062.
54. Kristensen, L.S., Hansen, J.W., Kristensen, S.S., Tholstrup, D., Harslof, L.B., Pedersen, O.B., et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin. Epigenetics., 8(1), 2016, 95.
55. Li, Z., Guo, X., Tang, L., Peng, L., Chen, M., Luo, X., et al. Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing. Tumour Biol., 2016.
56. Majchrzak-Celinska, A., Paluszczak, J., Kleszcz, R., Magiera, M., Barciszewska, A.M., Nowak, S., et al. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J. Appl. Genet. 54:3 (2013), 335–344.
57. Matthaios, D., Balgkouranidou, I., Karayiannakis, A., Bolanaki, H., Xenidis, N., Amarantidis, K., et al. Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. Oncol. Lett. 12:1 (2016), 748–756.
58. Skvortsova, T., Rykova, E., Tamkovich, S., Bryzgunova, O., Starikov, A., Kuznetsova, N., et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer 94:10 (2006), 1492–1495.
59. Warton, K., Samimi, G., Methylation of cell-free circulating DNA in the diagnosis of cancer. Front. Mol. Biosci., 2, 2015, 13.
60. Hoon, D.S., Spugnardi, M., Kuo, C., Huang, S.K., Morton, D.L., Taback, B., Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:22 (2004), 4014–4022.
61. Marini, A., Mirmohammadsadegh, A., Nambiar, S., Gustrau, A., Ruzicka, T., Hengge, U.R., Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J. Invest. Dermatol. 126:2 (2006), 422–431.
62. Salvianti, F., Orlando, C., Massi, D., De Giorgi, V., Grazzini, M., Pazzagli, M., et al. Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma. Front. Mol. Biosci., 2, 2015, 76.
63. Koyanagi, K., Mori, T., O'Day, S.J., Martinez, S.R., Wang, H.J., Hoon, D.S., Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res. 66:12 (2006), 6111–6117.
64. Hoshimoto, S., Kou, C.T., Chong, K.K., Takeshima, T.L., Takei, Y., Li, M.W., et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J. Investig. Dermatol. 132:6 (2012), 1689–1697.
65. Mori, T., O'Day, S.J., Umetani, N., Martinez, S.R., Kitago, M., Koyanagi, K., et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J. Clin. Oncol. 23:36 (2005), 9351–9358.
66. Salvianti, F., Orlando, C., Massi, D., De Giorgi, V., Grazzini, M., Pazzagli, M., et al. Tumor-related methylated cell-free DNA and circulating tumor cells in melanoma. Front. Mol. Biosci., 2(76), 2016.
67. Papadopoulou, E., Davilas, E., Sotiriou, V., Georgakopoulos, E., Georgakopoulou, S., Koliopanos, A., et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann. N. Y. Acad. Sci. 1075 (2006), 235–243.
68. Ponomaryova, A.A., Rykova, E.Y., Cherdyntseva, N.V., Skvortsova, T.E., Dobrodeev, A.Y., Zav'yalov, A.A., et al. Potentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patients. Lung Cancer 81:3 (2013), 397–403.
69. Begum, S., Brait, M., Dasgupta, S., Ostrow, K.L., Zahurak, M., Carvalho, A.L., et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17:13 (2011), 4494–4503.
70. Bondurant, A.E., Huang, Z., Whitaker, R.S., Simel, L.R., Berchuck, A., Murphy, S.K., Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. Gynecol. Oncol. 123:3 (2011), 581–587.
71. Liggett, T.E., Melnikov, A., Yi, Q., Replogle, C., Hu, W., Rotmensch, J., et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 120:1 (2011), 113–120.
72. Liggett, T.E., Melnikov, A.A., Marks, J.R., Levenson, V.V., Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int. J. Cancer. 128:2 (2011), 492–499.
73. Zhang, J., Zhang, J., Li, M., Wu, Y., Fan, Y., Zhou, Y., et al. Methylation of RAR-beta2, RASSF1A, and CDKN2A genes induced by nickel subsulfide and nickel-carcinogenesis in rats. Biomed. Environ. Sci. 24:2 (2011), 163–171.
74. Thress, K.S., Brant, R., Carr, T.H., Dearden, S., Jenkins, S., Brown, H., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90:3 (2015), 509–515.
75. Hayashi, M., Chu, D., Meyer, C.F., Llosa, N.J., McCarty, G., Morris, C.D., et al. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer 122:19 (2016), 3015–3023.
76. Reid, A.L., Freeman, J.B., Millward, M., Ziman, M., Gray, E.S., Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin. Biochem. 48:15 (2015), 999–1002.
77. Horn, S., Figl, A., Rachakonda, P.S., Fischer, C., Sucker, A., Gast, A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 339:6122 (2013), 959–961.
78. Nagore, E., Heidenreich, B., Rachakonda, S., Garcia-Casado, Z., Requena, C., Soriano, V., et al. TERT promoter mutations in melanoma survival. Int. J. Cancer 139:1 (2016), 75–84.
79. Nagore, E., Heidenreich, B., Requena, C., Garcia-Casado, Z., Martorell-Calatayud, A., Pont-Sanjuan, V., et al. TERT promoter mutations associate with fast-growing melanoma. Pigment. Cell Melanoma Res. 29:2 (2016), 236–238.
80. Griewank, K.G., Murali, R., Puig-Butille, J.A., Schilling, B., Livingstone, E., Potrony, M., et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J. Natl. Cancer Inst., 106(9), 2014.
81. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371:23 (2014), 2189–2199.
82. Ekedahl, H., Lauss, M., Olsson, H., Griewank, K.G., Schadendorf, D., Ingvar, C., et al. High TERT promoter mutation frequency in non-acral cutaneous metastatic melanoma. Pigment Cell Melanoma Res. 29:5 (2016), 598–600.
83. Akbani, R., Akdemir, A.C., Aksoy, B.A., Albert, M., Ally, A., Amin, B.S., et al. The cancer genome atlas network, genomic classification of cutaneous melanoma. Cell 161:7 (2015), 1681–1696.
84. Huang, S.K., Hoon, D.S., Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol. Oncol. 10:3 (2016), 450–463.
85. Pengelly, R.J., Gibson, J., Andreoletti, G., Collins, A., Mattocks, C.J., Ennis, S., A SNP profiling panel for sample tracking in whole-exome sequencing studies. Genome Med., 5(9), 2013, 89.
86. Momtaz, P., Pentsova, E., Abdel-Wahab, O., Diamond, E., Hyman, D., Merghoub, T., et al. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget 7:51 (2016), 85430–85436.
87. Li, Y., Pan, W., Connolly, I.D., Reddy, S., Nagpal, S., Quake, S., et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J. Neurooncol. 128:1 (2016), 93–100.
88. Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med., 8(346), 2016 346ra92.
89. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
90. Peters, S., Creelan, B., Hellmann, M.D., Socinski, M.A., Reck, M., Bhagavatheeswaran, P., et al. CT082-Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026. 2017.
91. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
92. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer. 16:5 (2016), 275–287.
93. Maker, A.V., Yang, J.C., Sherry, R.M., Topalian, S.L., Kammula, U.S., Royal, R.E., et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J. Immunother. 29:4 (2006), 455–463.